Indication
For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

Medicine details

Medicine name:
inotersen (Tegsedi)
SMC ID:
SMC2188
Pharmaceutical company
Akcea Therapeutics UK Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
12 August 2019
SMC meeting date:
02 July 2019
Patient group submission deadline:
06 May 2019